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Background: Autologous matrix-induced chondrogenesis (AMIC) is a single-stage alternative to autologous chondrocyte
implantation for treatment of localized cartilage defects of the knee. To our knowledge, no randomized controlled trial exists
comparing the 2 methods.
Purpose: To evaluate any difference in the outcome of AMIC as compared with collagen-covered autologous chondrocyte
implantation (ACI-C).
Study Design: Randomized controlled trial; Level of evidence, 2.
Methods: A prospective randomized controlled clinical trial was designed to assess any differences in the outcomes between ACI-
C and AMIC for the treatment of 1 chondral or osteochondral defects of the distal femur and/or patella. The inclusion period was
set to 3 years, and the aim was to include 80 patients (40 in each group). Patient inclusion was broad, with few exclusion criteria.
The primary outcome was change in Knee injury and Osteoarthritis Outcome Score (KOOS) at 2 years as compared with baseline.
The secondary outcomes were the number of failures in each group at 2 years and the change in KOOS subscale, Lysholm, and
pain visual analog scale (VAS) scores at 2 years as compared with baseline. A 2-sample t test with a significance level of P < .05
was used to compare the change in score from baseline between groups.
Results: A total of 41 patients over 3 years were included in the study: 21 in the ACI-C group and 20 in the AMIC group. All the
patients had prior surgery to the index knee. At 2-year follow-up, the clinical scores for both groups improved significantly from
baseline. No significant differences between groups were seen in the change from baseline for KOOS (AMIC, 18.1; ACI-C, 10.3),
any of the KOOS subscales, the Lysholm score (AMIC, 19.7; ACI-C, 17.0), or the VAS pain score (AMIC, 30.6; ACI-C, 19.6). Two
patients in the AMIC group had progressed to a total knee replacement by the 2-year follow-up as compared with none in the ACI-
C group.
Conclusion: At 2-year follow-up, no significant differences were found regarding outcomes between ACI-C and AMIC. Mid- and
long-term results will be important.
Registration: NCT01458782 (ClinicalTrials.gov identifier).
Keywords: cartilage repair; knee; autologous matrix-induced chondrogenesis; AMIC; autologous chondrocyte implantation;
ACI-C; clinical outcome
Patients hampered with impaired joint function attributed
to localized cartilage defects or early osteoarthritis of the
knee represent a major challenge for orthopaedic surgeons.
These patients have often exhausted conservative treatment
options and are not eligible for definitive treatment with a
total knee replacement owing to young age, participation in
high-demand activities, or lack of global osteoarthritis.
Defects in the hyaline cartilage may result from acute
trauma, repetitive microtrauma, early osteoarthritis, or
osteochondritis dissecans and can produce symptoms such
as pain, catching, locking, swelling, and stiffness.
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Given its avascular and aneural nature, hyaline carti-
lage has limited self-healing potential. Superficial defects
do not cause hemorrhage or induce a local acute inflamma-
tory response.5 Following the trauma, chondrocytes prolif-
erate and upregulate the production of matrix molecules,
but the surface is not restored.21,27 If the cartilage defect
penetrates the subchondral bone plate, the highly vascular-
ized bone marrow can aid in the healing process by forming
a blood clot containing chondroprogenitor cells, bioactive
molecules, and fibrin.33 This mainly produces type I colla-
gen and therefore fibrocartilage rather than hyaline carti-
lage.12 Fibrocartilage lacks the specialized viscoelastic
characteristics of hyaline cartilage and degenerates faster.
It is commonly accepted that over time, a cartilage injury
increases the risk of osteoarthritis formation regardless of
depth or origin.17
Over the past 3 decades, great efforts have been made to
advance the field of tissue engineering and cartilage repair
around the world. Modification of old techniques and devel-
opment of new methods have been conducted in search of the
“holy grail”—the regeneration of hyaline cartilage with
seamless integration into the cartilage defect. However, sev-
eral leading researchers in the field have stated that no sig-
nificant progress has been made during the past decade.17,22
Few large randomized controlled trials (RCTs) of high qual-
ity exist comparing the vast numbers of techniques. Even
more worrisome is the lack of trials comparing new techni-
ques with a nonsurgical approach. In 2017, Devitt et al9 con-
ducted a systematic review of RCTs in search of the most
appropriate surgical treatments for cartilage defects of the
knee. Out of 540 articles initial identified, only 10 were found
methodically sufficient to be included in the review. A most
effective treatment could not be determined.
Current surgical repair strategies comprise bone marrow
stimulation and transplantation of osteochondral plugs or
chondrocytes. The bone marrow–stimulating procedures
include drilling/chondroplasty/microfracture and modifica-
tions of these techniques, such as autologous matrix-
induced chondrogenesis (AMIC). Steadman et al34,35
introduced microfracture as a modification of drilling in the
1990s. The chondral defect is stabilized and debrided, and a
specially designed awl is used to perforate the subchondral
bone plate, releasing bone marrow stem cells into the car-
tilage defect and resulting in repair tissue. A specific reha-
bilitation protocol with partial weightbearing and
continuous passive motion is considered crucial to optimize
the results after surgery. The AMIC technique was pub-
lished by Benthien and Behrens3 in 2011, and it combines
microfracture with a protective collagen membrane that
functions both as a scaffold and as containment for the
mesenchymal cells within the defect. Transplantation can
be done by replacing the damaged cartilage with 1 osteo-
chondral plugs (autograft or allograft) or by introducing
autologous chondrocytes into the defect (autologous chon-
drocyte implantation [ACI]).
ACI was described by Brittberg et al4 in 1994, and it
involves a 2-step procedure where a cartilage biopsy is
arthroscopically harvested from a nonweightbearing area
of the joint. The chondrocytes are released from the
biopsy, expanded in a laboratory, and implanted with a
periosteal flap to cover the cartilage defect in a second
surgical procedure. The procedure has been refined with
a collagen membrane (ACI-C) instead of periosteum to
cover the defect, ameliorating the problem of hypertrophic
repair tissue. Other modifications, such as matrix-
assisted chondrocyte implantation (MACI) and character-
ized chondrocyte implantation (CCI), are currently being
investigated.
Compared with ACI-C, the marrow stimulation proce-
dures are technically easier and less expensive,1 do not
require removal of healthy cartilage, are not dependent
on laboratory facilities to expand the chondrocytes in cul-
ture, and require only 1 surgical procedure. Complemen-
tary unloading/realignment procedures for the
patellofemoral joint and tibiofemoral joint have been useful
and are advocated by orthopaedic surgeons if indicated.20
To our knowledge, no RCTs comparing the results of
ACI-C versus AMIC currently exist. The objective of the
present study was to compare ACI-C and AMIC in a
randomized trial. We aimed to determine whether the cell
source (bone marrow vs autologous chondrocytes) affects
the outcome, given that all the other aspects of the
procedures are similar. All the included patients in our
study had 1 previous surgical procedures to the index
knee, and no patients with acute injuries were recruited
to the study. The results after 1 and 2 years of follow-up
are presented in this article.
METHODS
Study Design
The initial study plan was to include 80 patients over 3
years. The study was designed to be a 2-center study involv-
ing The University Hospital of North Norway, Tromsø, and
1 collaborating hospital in the region. The study site in
Tromsø was expected to do the majority of surgical proce-
dures. The collaborating site was terminated 1 year into the
trial because of unforeseen practical issues.
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We included patients with 1 chondral/osteochondral
lesions of the distal femur and/or patella as identified by
magnetic resonance imaging findings and/or previous
arthroscopies. The inclusion of patients was broad, with few
exclusion criteria (Table 1). Patients with signs of early oste-
oarthritis were accepted, but it was required that the sur-
geon had judged the main symptoms to be caused by 1
isolated cartilage defects suitable for biological repair. The
same senior orthopaedic surgeon (G.K.), experienced in both
techniques, evaluated all patients before they were included
in the study and was involved in all surgical procedures.
Signed informed consent was obtained prior to surgery,
and the protocol was approved by the regional ethics com-
mittee. Financial support was provided by the orthopaedic
department at The University Hospital of North Norway.
Patients were randomized into blocks of 10 through sealed
envelopes after inclusion in the study, but before surgery.
Baseline Assessment
Baseline clinical data from the Knee injury and Osteoar-
thritis Outcome Score (KOOS), Lysholm questionnaire, and
visual analog scale (VAS) for pain were obtained prior to
surgery. The degree of osteoarthritis at baseline was
assessed by the Kellgren-Lawrence score evaluated from
weightbearing radiographs of the index knee. Range of
motion, alignment, and ligament status were clinically
assessed.
Surgical Technique
The surgical techniques were modified to ensure that the
conditions for cartilage regeneration were kept as similar
as possible, with the major difference being the source of
the cells introduced into the defect—namely, the cultivated
autologous chondrocytes in ACI-C versus in vivo bone mar-
row cells in AMIC. The approach to the knee at the final
operation was done by a small arthrotomy appropriate to
the location of the defect. If several defects were
addressed, they were accessible with the same limited
arthrotomy. The defects were debrided to healthy sur-
rounding cartilage and down to the subchondral bone
plate, with removal of all the cartilage, including the cal-
cified layer. A collagen type I/III patch (Chondro-Gide;
Geistlich Pharma), exactly covering the entire defect, was
sutured to the surrounding cartilage by 5.0 or 6.0
resorbable sutures and then sealed along the edges with
fibrin glue (Tisseel; Baxter). The stability of the patch was
assessed by flexing and extending the knee 5 times.
Autologous Matrix-Induced Chondrogenesis
A modified surgical technique was used, similar to the tech-
nique described by Benthien and Behrens.3 In contrast to
the original description, we used sutures around the edge,
and fibrin glue was applied only around the rim as for ACI-
C. After debridement, a 1.5-mm drill was used to perforate
the subchondral bone plate to a depth of 1 cm, thereby
mobilizing bone marrow stem cells into the defect. Care was
taken to leave areas of intact subchondral bone plate
between the drill holes. The collagen patch was then
sutured in place before fibrin sealant was applied.
Collagen-Covered
Autologous Chondrocyte Implantation
Second-generation ACI (ACI-C) was used, similar to the
technique described by Brittberg et al.4 A *200-mg carti-
lage biopsy was arthroscopically harvested from a low
weightbearing area of the index knee 3 to 4 weeks prior
to index surgery. Patients were instructed to unload on
crutches for 2 to 4 days after the biopsy. Immediately after
harvest, the cartilage biopsy was mechanically and enzy-
matically digested to release the chondrocytes. The chon-
drocytes were serially expanded to passages 2 to 3 during 3
to 4 weeks and implanted into the debrided cartilage
defect. At least 1 million cells/cm2 were injected under the
sutured collagen patch, and a final suture and fibrin seal-
ant completed the transplantation. Care was taken not to
induce bleeding from the bottom of the defect before
transplantation.
Postoperative Rehabilitation
Continuous passive motion was performed with the Kinetec
Spectra Knee for four 1-hour sessions a day during the 2- to
5-day hospital stay. Continuous passive motion was discon-
tinued at discharge. The patients were allowed partial
weightbearing (15-20 kg) with crutches for the first 6
weeks. Only patients with defects in the patellofemoral
joint were issued a knee brace, restricting movement from
0 to 40 for 6 weeks. The brace was used continuously
during the 6 weeks. To mimic continuous passive motion,
indoor cycling was encouraged as soon as the pain and
swelling allowed it. A written exercise program designed
to increase range of motion and increase strength was given
to all the patients before departure. At 6 weeks, the reha-
bilitation progress was evaluated by a physical therapist at
our department. Further guided rehabilitation from a local
physical therapist was issued if needed.
Follow-up
Patients were evaluated at 1 and 2 years postoperatively by
1 of the 2 surgeons involved in the study. The evaluators
TABLE 1
Inclusion and Exclusion Criteria
Inclusion Criteria Exclusion Criteria
Age, 18-60 y
Informed consent signed by patient
Symptomatic cartilage defects of
the knee >2 cm2
Inflammatory joint disease
Serious illness
Alcohol or drug abuse during
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were not blinded to treatment rendered. The same clinical
scores obtained at baseline were repeated at each follow-up.
Weightbearing anteroposterior and lateral radiographs of
the knee were obtained 2 years after surgery.
Outcomes
The primary outcome was defined as change in the KOOS
score versus baseline at every follow-up. Secondary out-
come measures were treatment failure and change from
baseline in KOOS subscales, Lysholm score, and VAS pain
score. Assessment of progression of osteoarthritis by
change in Kellgren-Lawrence score was not done at the 2-
year follow-up but is planned at the 5- and 10-year follow-
up.
Treatment failures were reported as either a “hard fail-
ure” or a “clinical failure.” A hard failure was defined as the
patients needing a new resurfacing procedure of the index
lesion or implantation of a knee prosthesis. A clinical
failure was defined as any deterioration in KOOS scores
at 2-year follow-up compared with baseline. Diagnostic
rearthroscopy or arthroscopy with debridement of synovia
or the defect was not considered a failure.
Statistical Methods
A sample size estimation based on a similar trial performed
by one of the authors (Knutsen et al24) indicated that 40
patients would be required in each group to demonstrate a
difference in change between the groups of at least 0.75 SD,
with a significance level of .05 and a power of 0.90. A positive
change (delta) in KOOS, Lysholm, and VAS scores repre-
sented improvement as compared with baseline for all the
scores. Comparison of mean delta between the groups was
performed with a 2-sample t test with a significance level of
P < .05. The normality assumption was assessed by descrip-
tive statistics. Comparison between the groups was per-
formed on the intention-to-treat (ITT) population. Missing
data from patients with hard failures and patients lost to
follow-up were obtained from the last observation carried
forward. A noninferiority analysis comparing AMIC with
ACI-C was performed by evaluation of the 95% CI of the
difference in delta KOOS at 2 years. A noninferiority margin
was not defined in the study protocol. Both the ITT and the
per-protocol (PP) populations were used for the noninferior-
ity analysis. In the PP population, patients with hard failure
and patients lost to follow-up were excluded from the data.
Bivariate correlation was examined with Pearson correla-
tion coefficients. A sensitivity analysis comparing the differ-
ence in delta KOOS, delta Lysholm, and delta VAS was
performed with the nonparametric Mann-Whitney U test.
SPSS (v 25; IBM) was used for statistical analysis.
RESULTS
Baseline Characteristics
A total of 44 patients were enrolled into the study between
October 2011 and November 2014. Given the technical and
practical aspects, all patients were included and underwent
surgery at The University Hospital of North Norway. One
patient did not undergo surgery during the study period,
and 2 were excluded during initial assessment owing to a
lack of symptoms, thus leaving 41 patients included in the
final study and representing the ITT population, where 21
patients were treated with ACI-C and 20 with AMIC
(Figure 1).
Patient and lesion characteristics are summarized in
Tables 2 and 3, respectively. The exact cause of the defect
was challenging to assess given the long duration of symp-
toms in many of the cases. No acute traumatic defects were
included in the study. All the patients had previous surgery
in the index knee. These included arthroscopic debride-
ment (33 patients), arthroscopic microfracture (21
patients), arthroscopic total and partial meniscectomy (15
patients), anterior cruciate ligament reconstruction (4
patients), drilling of osteochondritis dissecans defects (2
patients), and removal of loose bodies (3 patients). The har-
vest procedure in the ACI-C group was not regarded as
previous surgery. Ten patients in the AMIC group and 11
in the ACI-C group had previous microfracture performed
on the index knee, while the number of patients with pre-
vious microfracture on the index lesion was not recorded.
Both patients with prior drilling of an osteochondritis dis-
secans defect were in the ACI-C group, and it was the same
lesion that was addressed in our trial. In the 4 patients with
Figure 1. Trial progression flowchart. ACI-C, collagen-
covered autologous chondrocyte implantation; AMIC,
autologous matrix-induced chondrogenesis.
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anterior cruciate ligament reconstruction, the procedure
had been performed 9 to 10 years prior to index surgery.
One patient had 2 defects in the lateral femoral condyle.
Four patients with a single defect had a defect size <2.0
cm2, all in the ACI-C group. Three patients with 2
addressed lesions had a main defect >2.0 cm2 but a second-
ary defect <2.0 cm2: 2 in the AMIC-group and 1 in the ACI-
C-group. No patients had 2 defects where both were <2.0
cm2. One patient in the AMIC group with a patellar defect
had an additional realignment procedure (tibial tubercle
osteotomy and lateral release) at the index surgery because
of habitual patellar dislocations. The rehabilitation was as
for patellofemoral lesions. No other patients had realign-
ment or unloading procedures performed.
The preoperative mean KOOS was 58.5 in the ACI-C
group versus 54.1 in the AMIC group (P ¼ .42). The mean
Lysholm at baseline was 52.6 (ACI-C) versus 50.5 (AMIC)
and the mean VAS, 50.0 (ACI-C) versus 57.6 (AMIC).
Clinical Outcomes at 1 and 2 Years
All 2-year follow-ups were completed by December 15,
2016. At the 1-year follow-up, there were no hard failures,
and no patients were lost to follow-up. At 2 years, there
were 3 failures in the ACI-C group and 5 in the AMIC
group. Two patients in the AMIC group underwent total
knee replacement surgery at 21 and 23 months after the
primary surgery (hard failures). Their last observation data
were carried forward to the 2-year follow-up. One patient in
the AMIC group had missing data at 2 years and was clas-
sified as lost to follow-up at this time point. Data from the
last observation were carried forward. Characteristics of
TABLE 2
Baseline Characteristicsa (N ¼ 41)
ACI-C (n ¼ 21) AMIC (n ¼ 20)
Sex
Male 14 (66.7) 8 (40)
Female 7 (33.3) 12 (60)
Age at surgery, y 37.2 ± 10.8 (19-55) 38.3 ± 8.2 (24-55)




13 (61.9) 13 (65.0)
Osteoarthritis 0 (0) 2 (10.0)
Osteochondritis
dissecans
3 (14.3) 0 (0)
Other/unknown 5 (23.8) 5 (25.0)
No. of previous surgical
procedures in the same
knee
1 6 (28.6) 3 (15.0)
2 6 (28.6) 10 (50.0)
3 7 (33.3) 6 (30.0)
4 1 (4.8) 0 (0)
5 0 (0) 0 (0)
6 1 (4.8) 1 (5.0)
Microfracture 11 (52.4) 10 (50.0)
ACL reconstruction 2 (9.5) 2 (10.0)
Duration of symptoms, y 9.3 ± 5.5 (1-21) 9.4 ± 6.4 (1-23)
Ligament status:
instability
ACL 1 (4.8) 1 (5.0)
PCL 0 (0.0) 2 (10.0)
LCL 0 (0.0) 1 (5.0)
MCL 0 (0.0) 1 (5.0)
Alignment
Normal 17 (81.0) 14 (70.0)
Varus 3 (14.3) 1 (5.0)




Full 21 (100.0) 13 (65.0)
>90 0 (0.0) 6 (30.0)
Missing 0 (0.0) 1 (5.0)
Extension
Full 17 (81.0) 13 (65.0)
Deficit 4 (19.0) 6 (30.0)
Missing 0 (0.0) 1 (5.0)
Kellgren-Lawrence score
0 7 (33.3) 4 (20.0)
1 9 (42.9) 8 (40.0)
2 2 (9.5) 8 (40.0)
3 3 (14.3) 0 (0)
Score
KOOS 58.5 ± 15.7 54.1 ± 19.2
Lysholm 52.6 ± 11.6 50.5 ± 18.6
VAS pain 50.0 ± 20.1 57.6 ± 20.6
aValues are presented as mean ± SD (range) or n (%). ACI-C,
collagen-covered autologous chondrocyte implantation; ACL,
anterior cruciate ligament; AMIC, autologous matrix-induced
chondrogenesis; KOOS, Knee injury and Osteoarthritis Outcome
Score; LCL, lateral collateral ligament; MCL, medial collateral




ACI-C (n ¼ 21) AMIC (n ¼ 20)
Location of defects
Medial femoral condyle 7 (33.3) 7 (35.0)
Lateral femoral condyle 2 (9.5) 1 (5.0)
Trochlea 7 (33.3) 5 (25.0)
Patella 1 (4.8) 4 (20.0)
Trochlea and patella 2 (9.5) 2 (10.0)
Trochlea and medial
femoral condyle
2 (9.5) 1 (5.0)
No. of defects
1 17 (81.0) 16 (80.0)
2 4 (19.0) 4 (20.0)
Total defect size, cm2 4.9 ± 4.4 (1.2-21.5) 5.2 ± 2.4 (2.0-12.3)
ICRS grade
Main defect
3 16 (76.2) 17 (85.0)
4 5 (23.8) 3 (15.0)
Secondary defect
3 2 (50.0) 4 (100)
4 2 (50.0) 0 (0)
aValues are presented as mean ± SD (range) or n (%). ACI-C,
collagen-covered autologous chondrocyte implantation; AMIC,
autologous matrix-induced chondrogenesis; ICRS, International
Cartilage Repair Society.
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the patients with failure at 2 years are summarized in
Table 4.
The mean KOOS, Lysholm score, and VAS score
improved from baseline at both follow-ups (Figures 2-4).
Compared with baseline, the mean delta for the KOOS,
Lysholm score, and VAS score was significantly higher
than zero (highest P value ¼ .018) for all patients and in
both groups at both follow-ups.
TABLE 4






Surgery Age, y Localization Baseline 2 y Comments
Clinical failure
ACI-C 31 MFC 0 1.2 44.0 35.7 Diagnosed with fibromyalgia and possible ankylosing spondylitis
postsurgery. Receives disability benefits.
ACI-C 33 MFC 0 3.1 68.5 47.6 Got pregnant shortly after primary surgery.
ACI-C 51 MFC and
trochlea
3 4.2 and 0.8 82.7 52.4 MRI 1 y after surgery showed major degenerative changes.
AMIC 44 Trochlea
and MFC
2 7.5 and 4.8 67.3 60.7b Rearthroscopy 17 mo after surgery. Minimal regeneration
cartilage and osteophyte formation in the middle of the
trochlear defect. Debrided with bone cutter. Good filling of
medial condyle defect.
AMIC 35 MFC 2 3.8 97.0 88.7 PCL insufficient when tested by arthroscopy at primary surgery.
Not addressed. Satisfied at 1 y, but result had deteriorated at 2 y.
AMIC 38 MFC 0 2.0 70.8 68.5 Rearthroscopy within 1 y. Good filling of the defect. At 2 y, under
evaluation for fibromyalgia.
Hard failure
AMIC 55 MFC 2 6.0 26.2 26.2b Not satisfied at last follow-up after knee replacement.
AMIC 39 Trochlea 2 5.0 33.9 67.3b Lacking information after the knee replacement.
aACI-C, collagen-covered autologous chondrocyte implantation; AMIC, autologous matrix-induced chondrogenesis; K-L, Kellgren Lawr-
ence; KOOS, Knee injury and Osteoarthritis Outcome Score; MFC, medial femoral condyle; MRI, magnetic resonance imaging; PCL, posterior
cruciate ligament.


























Figure 2. Mean KOOS score at baseline and follow-up for
both intention-to-treat populations. Mean delta KOOS was
significantly higher than zero at 1 year: 9.7 (P ¼ .02) in the
ACI-C group and 15.0 (P ¼ .002) in the AMIC group. Mean
delta KOOS was significantly higher than zero at 2 years: 10.3
(P ¼ .008) in the ACI-C group and 18.1 (P ¼ .001) in the AMIC
group. Error bars represent 95% CIs. ACI-C, collagen-
covered autologous chondrocyte implantation; AMIC, autol-
ogous matrix-induced chondrogenesis; KOOS, Knee injury

























Figure 3. Mean Lysholm score at baseline and follow-up for
both intention-to-treat populations. Mean delta Lysholm score
was significantly higher than zero at 1 year: 12.0 (P ¼ .004) in
the ACI-C group and 16.7 (P < .001) in the AMIC group. Mean
delta Lysholm score was significantly higher than zero at 2
years: 17.0 (P < .001) in the ACI-C group and 19.7 (P ¼ .001)
in the AMIC group. Error bars represent 95% CIs. ACI-C,
collagen-covered autologous chondrocyte implantation;
AMIC, autologous matrix-induced chondrogenesis.
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At 2 years, the primary outcome mean delta KOOS was
10.3 in the ACI-C group and 18.1 in the AMIC group (P ¼
.17). As shown in Figure 5, the mean delta for all KOOS
subscales at 2 years was higher in the AMIC group, but the
difference was not statistically significant. The lowest
P value was for KOOS Sports/Recreation (ACI-C, 8.6;
AMIC, 22.0; P ¼ .08). The mean delta for the KOOS Symp-
toms and Sports/Recreation subscales was not statistically
significant higher than zero in the ACI-C group at 2 years.
The mean delta Lysholm score was higher in the AMIC
versus the ACI-C group at 2 years (19.7 vs 17.0), but this was
not significantly different (P ¼ .66). At 2 years, the mean
delta VAS was 19.6 in the ACI-C group versus 30.6 in the
AMIC group, but the finding was not significant (P ¼ .19).
A noninferiority analysis of AMIC versus ACI-C was per-
formed by evaluation of the 95% CI of the mean difference
in delta KOOS at 2 years. As advised in a noninferiority
trial, this was done for both the ITT and PP populations.6,26
As shown in Figure 6, a noninferiority margin of –3.45
would have been sufficient to statistically prove noninfer-
iority of AMIC as compared with ACI-C with a 0.05 alpha
level in the ITT population. For the PP population, the
noninferiority margin would have had to be –2.22 to claim
noninferiority.
A sensitivity analysis with the nonparametric indepen-
dent samples Mann-Whitney U test did not show any sta-
tistically significant differences between the groups with
regard to delta KOOS, delta Lysholm, or delta VAS pain
at either follow-up.
No significant correlations were found between the delta
KOOS or delta Lysholm at 2 years and the total size of the
defects, number of defects, age at surgery, body mass index,
or sex. Patients with previous microfracture surgery to the
index knee had a tendency toward a lower mean delta
KOOS at 2 years, but this difference was not significant
(Figure 7).
Two patients in both groups underwent rearthroscopy
within the first follow-up. One of the patients in the
ACI-C group underwent 2 rearthroscopies within the first
year. At 2 years, 3 patients in both groups had undergone






















Figure 4. Mean VAS pain score at baseline and follow-up for
both intention-to-treat populations. Mean delta VAS was sig-
nificantly higher than zero at 1 year: 22.8 (P< .001) in the ACI-C
group and 28.2 (P < .001) in the AMIC group. Mean delta VAS
was significantly higher than zero at 2 years: 19.6 (P ¼ .002) in
the ACI-C group and 30.6 (P < .001) in the AMIC group. Error
bars represent 95% CIs. ACI-C, collagen-covered autologous
chondrocyte implantation; AMIC, autologous matrix-induced













ACI-C Superior AMIC Superior
Figure 6. The mean with 95% CI for the difference between
the groups in delta KOOS for the per-protocol (PP) and
intention-to-treat (ITT) populations at 2 years. If the 95% CI
were located entirely to the right of zero, AMIC would have
been proven superior. If it were located entirely to the left of
zero, ACI-C would have been proven superior. For both
populations, the 95% CI crossed zero, meaning no superi-
ority was proven. The lowest noninferiority margin (–3.45) for
statistically proven noninferiority of AMIC as compared with
ACI-C is shown as the vertical dotted line. ACI-C, collagen-
covered autologous chondrocyte implantation; AMIC, autol-
ogous matrix-induced chondrogenesis; KOOS, Knee injury





















Figure 5. Comparison of mean delta for KOOS subscores in
each group at 2 years. Error bars represent 95% CIs. ADL,
activities of daily living; KOOS, Knee injury and Osteoarthritis
Outcome Score; QOL, quality of life; Sym, Symptoms.
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each group, underwent reoperation twice within the second
follow-up (Table 5).
No major acute complications, such as deep infection,
venous thrombosis, or cardiovascular events, were
observed in any of the groups.
DISCUSSION
This study is to our knowledge the first head-to-head com-
parison of the clinical outcomes for ACI-C versus AMIC.
Both groups significantly improved as compared with base-
line despite having 1 previous surgical procedures to the
index knee. AMIC patients had a higher mean improve-
ment in all clinical scores at 1 and 2 years as compared with
ACI-C. According to the primary outcome (mean delta
KOOS), our RCT showed no statistically significant supe-
riority of either ACI-C or AMIC at 2 years for treatment of
cartilage defects of the knee. This conclusion was supported
by the secondary outcome measures. However, we had
2 hard failures in the AMIC group at the 2-year mark, as
opposed to none in the ACI-C group.
Microfracture is widely accepted as a first-line treat-
ment option for small- to medium-sized cartilage defects
of the knee.29,37 For larger defects, many clinicians prefer
osteochondral plugs or a cartilage-regenerative technique,
such as ACI-C or MACI, because of concern about the effi-
cacy of microfracture to treat larger noncontained defects.
Four high-quality RCTs comparing microfracture and car-
tilage regenerative techniques with follow-up of 2 to 5
years were identified in the review article by Devitt
et al.9 Vanlauwe et al36 (microfracture vs CCI) and Knut-
sen et al23,24 (microfracture vs ACI-C) reported no differ-
ence between the groups at 5 years. In the early treatment
group (symptoms <3 years), Vanlauwe et al detected a
favorable result for CCI. Saris et al32 and Crawford
et al7 compared microfracture with MACI and found supe-
rior results in favor of MACI in some of their outcomes at 2
years. In 2016, Knutsen et al22 published long-term data
from a trial comparing microfracture and ACI-C. No dif-
ference was found between the “survivors.” Several stud-
ies have reported favorable short-time results for the
microfracture-based AMIC procedure.2,13,25 High-quality
studies comparing the outcomes of ACI-C and AMIC are,
however, lacking.
In our trial, patients treated with AMIC reported higher
mean delta in all outcomes examined as compared with
ACI-C, but given the low power following inclusion of fewer
patients than initially planned, no statistical superiority
could be shown. As a consequence, we performed a nonin-
feriority analysis of AMIC versus ACI-C. Interpreting a
superiority trial as a noninferiority trial may be feasible
given a set of conditions.6 In our trial, a noninferiority test
with a noninferiority margin of –3.45 would have yielded a
statistically significant noninferiority of AMIC as compared
with ACI-C for mean delta KOOS at 2 years. Since our trial
was designed as a superiority trial, no noninferiority mar-
gin was set in the protocol, and the noninferiority analysis
must be considered a sensitivity analysis. Improvement or
decline of 10 points has been suggested as a cutoff repre-
senting a minimal clinically important difference in the
KOOS score.31 A posttrial noninferiority margin of –5
therefore seems like a conservative estimate to statistically
prove that AMIC is noninferior to ACI-C with a significance
level of P < .05.
In the review article by Devitt et al,9 no significant differ-
ence was found in the failure rates of various techniques in
any trial up to 5 years. Knutsen et al22 found no significant
difference in treatment failure comparing ACI-C and micro-
fracture after 15 years of follow-up. A major limitation when
comparing the results of different cartilage repair techni-
ques is the diverging definition of failure. Filardo et al11
recommended that a failure be regarded as patient-
reported knee scores that fail to remain improved (>10
points) from baseline or revision surgery with active manip-
ulation at the index lesion. In our trial, failure was defined
as any deterioration of the KOOS score and/or a resurfacing/
joint replacement procedure. This definition led to 5 failures
in the AMIC group and 3 in the ACI-C group at 2 years. Two
patients in the AMIC group became hard failures when they
underwent a knee replacement operation within 2 years;
both patients had a Kellgren-Lawrence score of 2 prior to
surgery. The relative number of patients with failure was
higher in the AMIC group at 2 years. Most cases classified as
failure had some factors that could have contributed to the
unfavorable outcome (see Table 4). In the future, we should
aim toward a uniform definition of failure to be used in RCTs
comparing different techniques for cartilage repair.
The assumed cell source differs fundamentally between
the marrow stimulation techniques and the chondrocyte
transplantation techniques. Chondrocytes and mesenchy-
mal stem cells both demonstrate a potential to build
hyaline-like cartilage in laboratory models,10,19 but in clin-
ical trials, the resulting repair tissue is often a mix of fibro-
cartilage and hyaline cartilage. In their histological
examination of 67 biopsies from patients treated with
ACI-C (n ¼ 32) or microfracture (n ¼ 35), Knutsen et al24
































Figure 7. Mean delta KOOS at 2 years in patients with and
without previous microfracture to the index knee, P ¼ .79.
Error bars indicate 95% CI. KOOS, Knee injury and Osteoar-
thritis Outcome Score.
8 Fossum et al The Orthopaedic Journal of Sports Medicine
patients treated with ACI, but the difference was not sig-
nificant. The highest-quality predominantly hyaline carti-
lage was produced in 6 (19%) patients with ACI and 4 (11%)
with microfracture. Saris et al32 presented microscopically
similar repair tissue quality when comparing MACI and
microfracture. In addition, several studies have shown no
correlation between the quality of the regeneration tissue
and the clinical outcome.23 The same conclusion was made
in a study from our group, in which the surplus chondro-
cytes from the ACI-C group in this trial were used to inves-
tigate any correlation between in vitro chondrogenic
potential and clinical outcome.18
The exact mechanism behind the formation of repair tis-
sue is poorly understood for both marrow stimulation and
chondrocyte transplantation. Conflicting evidence exists
about the fate of the transplanted chondrocytes and how
they contribute to cartilage regeneration. Grande et al15
found only 8% of the repair cells to be transplanted chon-
drocytes in a rabbit model. Mierisch et al28 were able to
detect transplanted transgenic chondrocytes labeled with
enhanced green fluorescent protein in the defect, but they
did not appear to form repair tissue, and they decreased in
number with time. Hirschmann et al16 and Dell’Accio et al8
found, using different labeling techniques, that the trans-
planted chondrocytes could persist in the defect and become
a part of the repair tissue. Elvenes et al10 demonstrated in
2009 that the bone marrow collected from a single
“microfracture hole” in the middle of a cartilage defect con-
tained mesenchymal progenitor cells with the potential to
transform into cartilage-forming cells.
It seems as though the microfracture technique is capa-
ble of generating repair tissue of the same quality as the cell
transplantation techniques, but the risk of fibrocartilage
formation is higher. This could be from the lack of scaffold-
ing and containment. One could even argue that the mar-
row stimulation and cell transplantation techniques, from a
biological and biomechanical point of view, are basically the
same.17 During preparation of the lesion prior to chondro-
cyte transplantation, some degree of bleeding from the floor
of the defect usually occurs, thereby inducing a spontane-
ous repair response from the bone marrow compartment.
From our trial, it seems as if the source of the cells plays an
inferior role with regard to short-term clinical outcome.
The main limitation of our trial is the small number of
patients in each group. After 3 years, we had included 41
patients. We estimate that at least 3 more years would be
needed to reach the 80 patients called for by the power
calculation, and we decided to end the inclusion of patients
for economic and practical reasons.
Another limitation of the study design is the broad inclu-
sion criteria used. This led to heterogeneity regarding the
location of defects, number of defects, etiology of the
defects, duration of symptoms, and age for the group as a
whole. A difference in sex distribution was observed, with a
higher percentage of women in the AMIC group. In a study
from 2010, Gille et al14 reported a significantly higher clin-
ical score in males treated with AMIC than in females. If
female patients have a poorer outcome than male patients,
this would have affected our results for the AMIC group.
However, other trials,13 including our own, have not shown
the same correlation. Four patients in the ACI-C group
were, at the time of final surgery, shown to have a total
defect size smaller than the size described in the inclusion
criteria. This was due to overestimation of the nondebrided
defect size during arthroscopy. These patients were not
excluded from the study, and their results could have
inflated the outcome of the ACI-C group. Many patients
had signs of early osteoarthritis, even at baseline, but no
patients were included who were clear candidates for uni-
compartmental/total knee replacement or osteotomy.
Unloading braces were not used for lesions in the femoro-
tibial articulation, but any negative effect that this prac-
tice could have on the outcome scores would be applicable
to both groups.
TABLE 5






ACI-C 5; 10 Pain; pain Patella Good filling of defect, scar tissue in front of and medial to the patella,
debridement; still good filling of the defect, debridement
ACI-C 5 Hydrops and
catching
Trochlea Loosening of part of the collagen membrane, good filling of the defect,
debridement
ACI-C 16 Pain and catching LFC Operated by “other” surgeon, no mentioning of the defect, synovitis,
debridement
AMIC 7; 24 Acute pain and
swelling;
persistent pain
Trochlea Good filling of the defect in trochlea, no filling of small defect in MFC
where microfracture was performed at initial surgery, new
microfracture in MFC; adequate filling of the defect, healing of defect
in MFC, some general osteoarthritis
AMIC 12 Increasing pain and
stiffness
MFC Good filling of defect, some scar tissue and synovitis, debridement




Sparse regeneration cartilage in the defect with an osteophyte in the
middle, removal of the osteophyte, general debridement
aACI-C, collagen-covered autologous chondrocyte implantation; AMIC, autologous matrix-induced chondrogenesis; LFC, lateral femoral
condyle; MFC, medial femoral condyle.
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The broad inclusion of patients might have led to the
inclusion of patients with some degree of a chronic pain
condition. No acute lesions were included in the trial, and
this could have had a negative impact on the outcome
scores in both groups.36 Previous microfracture is known
to negatively affect the outcome of subsequent cartilage
regeneration procedures.30 Although we saw the same ten-
dency in our study, the disadvantage was equally distrib-
uted between the groups. Since the aim of the trial was to
compare the results of AMIC versus ACI-C and not to eval-
uate the effectiveness of the treatments, we do not consider
the broad inclusion criteria a major limitation of the trial’s
conclusion. The heterogeneity of the population and the
chronicity of the defects make it more relevant to extrapo-
late the results of our study to the typical group of patients
seen in a clinical setting.
CONCLUSION
This RCT comparing ACI-C and AMIC as a treatment for
cartilage defects of the knee indicated that the 2 treatments
result in similar clinical outcomes at 2-year follow-up. The
patients in this study are scheduled for 5- and 10-year
follow-ups. If the conclusion of the present study stands
and is confirmed by further clinical trials, AMIC could be
considered an equal alternative to techniques based on
chondrocyte transplantation for treatment of cartilage
defects of the knee. If considering that AMIC is a less
expensive 1-step procedure, one could even argue that
AMIC should be preferred. Further basic and clinical
research is needed in this field, as all available surgical
methods today are imperfect for cartilage repair.
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